- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00001085
A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients
A Randomized, Double-Blind, Phase II Study of 141W94 (VX-478) Monotherapy vs. 141W94 (VX-478) Plus ZDV Plus 3TC in HIV Infected Individuals
To determine the proportion of patients whose plasma HIV-1 RNA level remains below a detectable level (less than 500/ml) after 24 weeks of study therapy with either 141W94 monotherapy or 141W94 plus zidovudine (ZDV) and lamivudine (3TC). To determine the safety and tolerability of 141W94 monotherapy and the combination of 141W94 plus 3TC in patients with HIV infection.
Although dramatic inhibition of HIV-1 replication is achieved with ritonavir or indinavir monotherapy, in both cases maximum suppression required combination treatment together with nucleoside analog RT inhibitors. This study tests the hypothesis that monotherapy with 141W94 doses that result in Cmin levels far in excess of the IC90 corrected for plasma protein binding for HIV-1 can achieve the same virologic and immunologic effects in terms of magnitude and durability, as has been observed with combinations of other protease inhibitors plus nucleoside analogs.
연구 개요
상세 설명
Although dramatic inhibition of HIV-1 replication is achieved with ritonavir or indinavir monotherapy, in both cases maximum suppression required combination treatment together with nucleoside analog RT inhibitors. This study tests the hypothesis that monotherapy with 141W94 doses that result in Cmin levels far in excess of the IC90 corrected for plasma protein binding for HIV-1 can achieve the same virologic and immunologic effects in terms of magnitude and durability, as has been observed with combinations of other protease inhibitors plus nucleoside analogs.
In this randomized, double-blind study, patients' HIV RNA is screened 30 days prior to entry. Patients satisfying enrollment criteria must have been on a stable antiretroviral regimen for 30 days prior to study screening and remain on the same regimen until entry. Patients are stratified based on the screening HIV-1 RNA copy number obtained within 30 days of entry: 5,000 - 50,000 copies/ml versus greater than 50,000 copies/ml. In addition, patients are stratified based on previous antiretroviral use: naive versus experienced. Patients are randomized to one of 2 treatment arms: Arm A - 141W94, plus Zidovudine (ZDV) and Lamivudine (3TC) or Arm B - 141W94, plus ZDV placebo and 3TC placebo.
[AS PER AMENDMENT 8/25/97: Patients assigned to the monotherapy arm are advised to discontinue their study medication immediately and initiate antiretroviral therapy with indinavir, nevirapine, stavudine and 3TC, as outlined in ACTG 347 roll-over protocol, ACTG 373. Patients in the three-drug arm continue on study therapy.] [AS PER AMENDMENT 12/19/97: Patients receive study treatment for 56 weeks and are followed through week 68.]
연구 유형
등록
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- Alabama Therapeutics CRS
-
-
California
-
Los Angeles, California, 미국, 900331079
- USC CRS
-
-
Colorado
-
Aurora, Colorado, 미국, 80262
- University of Colorado Hospital CRS
-
-
Florida
-
Miami, Florida, 미국, 331361013
- Univ. of Miami AIDS CRS
-
-
Georgia
-
Atlanta, Georgia, 미국, 30308
- The Ponce de Leon Ctr. CRS
-
-
Illinois
-
Chicago, Illinois, 미국, 60612
- Cook County Hosp. CORE Ctr.
-
Chicago, Illinois, 미국, 60611
- Northwestern University CRS
-
Chicago, Illinois, 미국, 60612
- Rush Univ. Med. Ctr. ACTG CRS
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02118
- Bmc Actg Crs
-
Boston, Massachusetts, 미국, 02215
- Beth Israel Deaconess Med. Ctr., ACTG CRS
-
-
Missouri
-
Saint Louis, Missouri, 미국
- Washington U CRS
-
Saint Louis, Missouri, 미국, 63112
- St. Louis ConnectCare, Infectious Diseases Clinic
-
-
New York
-
New York, New York, 미국, 10016
- NY Univ. HIV/AIDS CRS
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 275997215
- Unc Aids Crs
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- Hosp. of the Univ. of Pennsylvania CRS
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
Concurrent Medication:
Allowed:
- Chemoprophylaxis for Pneumocystis carinii pneumonia is required for all patients who have a CD4 cell count <= 200 cells/mm3.
- Topical and/or oral antifungal agents, except for those listed in excluded medications.
- Treatment, maintenance or chemoprophylaxis with approved agents for opportunistic infections as clinically indicated, unless listed in excluded medications.
- All antibiotics as clinically indicated.
- Systemic corticosteroid use for <= 21 days for acute problems is permitted as medically indicated; chronic systemic corticosteroid use is not permitted.
- Recombinant erythropoietin and granulocyte colony-stimulating factor as medically indicated.
Regularly prescribed medications such as:
- antipyretics, analgesics, allergy medications, antidepressants, sleep medications, oral contraceptives (a barrier method is also required for this study), megestrol acetate, testosterone or any other medications, as medically indicated.
- Alternative therapies such as vitamins, acupuncture and visualization techniques are permitted (excluding herbal medications).
NOTE:
- Patients should report the use of these therapies; alternative therapies will be recorded.
Patients must have:
- HIV-1 infection as documented by ELISA and confirmed.
- >= 5,000 HIV-1 RNA copies/ml (within 30 days prior to study entry).
- CD4 cell count >= 50 cells/mm3 within 60 days prior to study entry.
- Signed, informed consent for patients < 18 years of age.
Prior Medication: Required:
- Patients must be on a stable antiretroviral regimen for 30 days prior to study screening and remain on the same regimen until entry.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Any active infection requiring acute treatment within 14 days prior to entry.
- A malignancy that requires systemic therapy other than minimal Kaposi's sarcoma.
NOTE:
- Patients with minimal Kaposi's sarcoma, defined as <= 5 cutaneous lesions and no visceral disease or tumor-associated edema, will be allowed to enroll as long as they do not require systemic therapy for Kaposi's sarcoma.
Patients with the following prior symptoms and conditions are excluded:
- Inability to tolerate ZDV 500-600 mg daily if ZDV was administered previously. Intolerance to ZDV is defined as any grade toxicity that resulted in a dose reduction or termination of ZDV.
Prior Medication:
Excluded:
- Any 3TC therapy prior to entry.
- Any HIV-1 protease inhibitor therapy prior to study entry (e.g., saquinavir, ritonavir, indinavir, nelfinavir, 141W94).
- Any immunomodulator therapy within 30 days prior to entry.
- Active immunization within 30 days prior to entry.
Any antiretroviral therapy change within 30 days prior to study screening.
1. Concurrent use of non-protocol specified antiretroviral agents; either investigational or licensed.
- Immunomodulators that affect immunologic or virologic indices such as systemic corticosteroids, thalidomide, or cytokines.
- Concomitant use of rifabutin and/or rifampin.
- Investigational drugs other than 141W94/VX-478.
- Systemic cytotoxic chemotherapy.
- Oral astemizole (Hismanal), carbamazepine (Tegretol), dexamethasone (Decadron), ketoconazole (Nizoral), itraconazole (Sporanox), phenobarbital, phenytoin (Dilantin), terfenadine (Seldane), cisapride (Propulsid), triazolam (Halcion) and midazolam (Versed).
- Herbal medications.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
공동 작업자 및 조사자
수사관
- 연구 의자: Gulick R
간행물 및 유용한 링크
일반 간행물
- Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R, Kuritzkes DR. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis. 1999 Apr;179(4):808-16. doi: 10.1086/314668.
- Murphy R, Degruttola V, Gulick R, D'Aquila R, Eron J, Sommadossi JP, Smeaton L, Currier J, Tung R, Kuritzkes D. 141W94 with or without zidovudine/3TC in patients with no prior protease inhibitor or 3TC therapy-ACTG 347. Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:175 (abstract no 512)
- Eron JJ Jr, Smeaton LM, Fiscus SA, Gulick RM, Currier JS, Lennox JL, D'Aquila RT, Rogers MD, Tung R, Murphy RL. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). J Infect Dis. 2000 May;181(5):1622-8. doi: 10.1086/315447. Epub 2000 Apr 26.
- Eron J, Smeaton L, Degruttola V, Schock J, Fiscus S, Tung R, Gulick R, Murphy R. The effects of amprenavir (APV) alone or in combination with ZDV/3TC, on HIV-1 levels in semen: a substudy of ACTG 347. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:109 (abstract no 222)
연구 기록 날짜
연구 주요 날짜
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ACTG 347
- 11317 (레지스트리 식별자: DAIDS ES)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
HIV 감염에 대한 임상 시험
-
Hospital Clinic of Barcelona완전한
-
CDC FoundationGilead Sciences알려지지 않은
-
University of WashingtonNational Institute of Mental Health (NIMH)모병
-
University of Minnesota빼는HIV 감염 | HIV/에이즈 | 에이즈 | 보조기구 | 에이즈/HIV 문제 | 에이즈와 감염미국
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS Foundation완전한파트너 HIV 테스트 | 부부 에이즈 상담 | 커플커뮤니케이션 | HIV 발병률카메룬, 도미니카 공화국, 그루지야, 인도
-
Michael HoelscherClinton Health Access Initiative Inc.; Instituto Nacional de Saúde (INS), Ministério da... 그리고 다른 협력자들모집하지 않고 적극적으로HIV, 신생아 HIV 조기 진단(EID), 현장 진료 검사(PoC)모잠비크, 탄자니아
-
Allegheny Singer Research Institute (also known...모집하지 않고 적극적으로
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)완전한
-
Erasmus Medical Center모병
-
Erasmus Medical Center모집하지 않고 적극적으로
라미부딘에 대한 임상 시험
-
Makerere UniversityMassachusetts General Hospital완전한
-
Thomas Benfield모병HIV 감염 | 비만 | 신부전 | 골다공증 | 에이즈 | 살찌 다 | HIV 지방이영양증덴마크
-
University of Colorado, DenverNational Institute of Allergy and Infectious Diseases (NIAID); University of Hawaii완전한
-
Fundacion SEIMC-GESIDAViiV Healthcare완전한
-
University Hospital, CaenMerck Sharp & Dohme LLC아직 모집하지 않음
-
Assistance Publique - Hôpitaux de Paris완전한
-
Obafemi Awolowo UniversityLondon School of Hygiene and Tropical Medicine; University of California, San Diego; University... 그리고 다른 협력자들완전한
-
Harvard School of Public Health (HSPH)National Institute of Allergy and Infectious Diseases (NIAID)종료됨